Pam Patdu

Medical Oncologist

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 PICC-2 | dMMR/MSI-H locally advanced CRC

➕ Toripalimab + celecoxib

📈 pCR: 89% vs 69% (p=0.014)
🏥 Surgery: 96% vs 93%
🛡️ Grade ≥3 TRAEs: 5% vs 7%

🚀 COX-2 inhibition may further enhance neoadjuvant immunotherapy.

🔗 https://t.co/j2yUUwsJ8H
@OncoAlert

[Yakup Ergün @dr_yakupergun]

Algorithm for Systemic Therapy in HER2-Positive Breast Cancer

(Based on NCCN and ESMO guidelines; recommendations in gray areas reflect the St. Gallen 2025 consensus and, in part, my own clinical judgment)

[Oncology Brothers @OncBrothers]

Here is the table for 7 studies we touched on during our Breats Cancer highlights discussion from #ASCO26 w/ @hoperugo

✅ #OPTIMA
✅ #lidERA
✅ #VIKTORIA1
✅ #KN522
✅ #ASCENT03 & #ASCENT04
✅ #TropionBreast02

#bcsm #OncTwitter #MedTwitter @OncoAlert @OncUpdates

[Rohit Malde @roxboxfix]

Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice

(Lancet Gastroenterology & Hepatology, 2026)

[Jimmie48 Photography @JJlovesTennis]

Sometimes you just instantly know that something's the photo of the day...maybe the tournament even.

I can't recall ever shooting anything similar to this.

[Pam Patdu @pam_patdu]

yeeeeeeah! #AlexEala

[Tennis Channel @TennisChannel]

Advantage, Eala. 🚨

She takes the opening set tiebreak 11-9 over defending champion Iga Swiatek. 👀

#Wimbledon

[Dr. Gee @askgodswill]

@EricTopol The 5-year lead time is the easy part. Prediction isn't prevention until it's paired with an intervention arm. The plasma proteome flags risk before histology, but the hard problem is separating destined-to-progress from indolent biology, or we just industrialize overdiagnosis.

[Diego A. Díaz-García @diegoadiazg]

🫁 Perioperative EGFR-Mutant NSCLC.

Adjuvant osimertinib remains the reference standard in resected EGFR-mutant NSCLC based on mature DFS, OS, and CNS benefit from ADAURA.
Emerging perioperative EGFR TKI strategies are promising, although mature survival data are still needed before redefining standards of care.

📖 Cancer Treatment Reviews
DOI 👉🏻 https://t.co/LJxKcuBG49

#CánCare #NSCLC #EGFR #LungCancer

[Open Medicine Insights @OpenMedInsights]

Cancer of Unknown Primary (CUP): updated ESMO Clinical Practice Guideline

In one of the most challenging scenarios in oncology, @myESMO provides a comprehensive roadmap for:

🔬 Diagnostic algorithm & pathology workup
🧬 Molecular profiling integration
💊 Evidence-based systemic strategies
📅 Structured follow-up recommendations
CUP is no longer “diagnosis of exclusion” — precision diagnostics are redefining management.
🔗 Full guideline:
https://t.co/qeRtomOsrT
@fatimacardoso , @stolaney1 , @LoiSher
#Oncology #CUP #PrecisionOncology #ESMOGuidelines #CancerCare

[Oncology Brothers @OncBrothers]

This is the treatment algorithm we’ve used during our discussion with @KalinskyKevin for metastatic HR+ #BreastCancer

#OncTwitter #MedX @OncUpdates @OncoAlert #bcsm

[Oscar Tahuahua @drtahuahua]

Can we stop #immunotherapy at 2 years in advanced NSCLC?

I-STOP study (n=173, PD-1/PD-L1 monotherapy)

OS NR in either group (HR 1.22)
PFS shorter if stopped (35.6 mo vs NR; HR 2.16)
Higher risk in PD-L1 ≤50%, KRASm and brain mets
Rechallenge worked (ORR 62.5%).

Observational, small discontinuation cohort.
Not for everyone
https://t.co/2tz2lhBqZ6 @OncoAlert #lcsm #NSCLC

[OncoAlert @OncoAlert]

OncoAlert🚨The #AUC3 WEEK 2026

Their Publication is NOW OUTARTICLE HERE: 👉 https://t.co/JdDy7wubN4

Presenter Dr. Brian Shuch 🇺🇸
Cytoreductive nephrectomy for advanced disease: CON

Patients need control of their systemic disease and our better systemic therapy offers that Surgery upfront is rarely needed, and we have other ways to palliate We don’t need to answer the same questions every treatment “era” if that treatment is not any better. We can consider surgery later, maybe if it means removing the site of progression or making NED

@DrRanaMcKay
@montypal
@DrRosenbergMSK
@Wanling50578056
@Dr_Aggen
@AlbigesL
@apolo_andrea
@OncoBellmunt
@bergsa83
@bilenma
@BraunMDPhD
@drjefstathiou
@PGrivasMDPhD
@shilpaonc
@arihakimi
@HHammersMD
@DrDanielHeng
@MichelleDunno17
@EJonasch
@koshkin85
@advocatekidneys
@UrogerliMD
@SurenaMatinMD
@maughanonc
@BradMcG04
@JoshMeeks
@motzermd
@AndreaNecchi
@SimaPorten
@tompowles1
@brian_rini
@sonpavde
@ChadTangMD
@MichvdHeijden
@VincentWenxinXu
@TiansterZhang
@Mustafajsalehmd
@mzugman
@DrChoueiri
@AUC3_Official
#kidneyCancer #BladderCancer

[Journal of Clinical Oncology @JCO_ASCO]

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Read the full article. https://t.co/5NeGwiEV2c
#LungCancer #lcsm

[Pam Patdu @pam_patdu]

@DrRishabhOnco #2

[Oscar Tahuahua @drtahuahua]

We treat HR+/HER2– metastatic breast cancer with ET + CDK4/6 inh.

⚠️~75% of BRCA2 breast cancers are HR+

In a real-world cohort (n=4,283), BRCA1/2/PALB2 carriers had a mPFS of 9.9 vs 15.4 months (HR 1.61, p<0.001). OS was similar, likely from PARP rescue.

Same receptor status. Different biology.

Is it time to test PARP inhibitors in 1L, as we did in prostate cancer (amplitude trial)?
https://t.co/7ES45u9nmi @OncoAlert

[Rebecca Shatsky, MD @Dr_RShatsky]

There are multiple trials now showing improved overall survival in patients receiving carboplatin for TNBC. It’s really time we put the question of is carbo beneficial in TNBC to rest and more uniformly give taxane/carbo instead of taxane/cyclophosphamide in stage 1 TNBC. Taxol/carbo now has more robust TNBC specific data than TC. #TNBC #BreastCancer

[Hope Rugo @hoperugo]

Best of Sabcs west! @SABCSSanAntonio

[Jeffrey Velotta MD FACS @JVelottaMD]

The quicker you fit the necessary preop tests in for early stage lung cancer surgery the better your outcomes are https://t.co/sqnA487QzR$ @accpchest @STS_CTsurgery @AATSHQ @KPMedSchool @KPDOR @NLCRTnews @GO2forLungCancr @LUNGevity @ATSScholar @atscommunity

[Dr Akhil Santhosh MD DM MRCP(UK) @tuttsakhil]

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer - The Breast https://t.co/qJxqIaCTnT